FK 506 renal toxicity and lack of detectable cytochrome P-450 3A in the liver graft of a patient undergoing liver transplantation
Open Access
- 1 December 1994
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 20 (6) , 1472-1477
- https://doi.org/10.1002/hep.1840200615
Abstract
Many commonly used drugs are substrates for hepatic cytochrome P-450 3A in human beings, and its role in the metabolism of potentially toxic immunosuppressants has been highlighted (cyclosporine, FK 506). One hundred fifty human liver grafts were biopsied before and after liver transplantation, and levels of cytochromes P-450 3A, 1A2, 2D6 and 2C were estimated by means of the Western-blot technique and correlated with histological appearance, glycogen content and clinical course. In 15 of the grafts, cyclosporine oxidase was also measured, and in 12 of 15 recipients, urinary 6β-hydroxycortisol excretion was assayed. A wide range of cytochrome P-450 3A values were observed (25 to 366 arbitrary units/mg; mean, 105 ± 63 arbitrary units/mg). In one graft (no. 730) no cytochrome P-450 3A was detectable on immunoblotting, despite increasing homogenate concentrations. In this sample, cytochromes P-450 1A2, 2D6, and 2C were present in normal ranges. Levels of cyclosporine oxidase and 6β-hydroxycortisol in the urine specimens of the recipient were found to be low. The recipient of graft 730 experienced reversible complications of FK 506 therapy despite adherence to the administration protocol and drug plasma level in the normal range. The subsequent appearance of the cytochrome P-450 3A was associated with the consequent tolerance of oral FK 506. The absence of detectable amounts of P-450 3A in one biopsy from a donated human liver graft dramatically emphasizes the extreme range of this enzyme levels and has important clinical implications. (Hepatology 1994;20:1472-1477).Keywords
This publication has 17 references indexed in Scilit:
- RELATIONSHIP BETWEEN GRAFT CYTOCHROME P-450 3A CONTENT AND EARLY MORBIDITY AFTER LIVER TRANSPLANTATION1Transplantation, 1993
- Incidence of adverse reactions to cyclosporine after liver transplantation is predicted by the first blood levelHepatology, 1993
- In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: Identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolismArchives of Biochemistry and Biophysics, 1992
- [33] Induction protocols for cytochromes P450IIIA in Vivo and in primary cultures of animal and human hepatocytesPublished by Elsevier ,1991
- A human cytochrome P-450 is recognized by anti-liver/kidney microsome antibodies in autoimmune chronic hepatitisBiochemical and Biophysical Research Communications, 1989
- OPTIMIZATION OF CYCLOSPORINE THERAPY IN RENAL TRANSPLANTATION BY A PHARMACOKINETIC STRATEGYTransplantation, 1988
- Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugsClinical Pharmacology & Therapeutics, 1988
- Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug.Proceedings of the National Academy of Sciences, 1987
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970